JDS Journal of Data Science 1683-86021680-743X1680-743X School of Statistics, Renmin University of China JDS1161C 10.6339/25-JDS1161C Discussion Discussion of “Power Priors for Leveraging Historical Data: Looking Back and Looking Forward”✩ GamaloMargaretMargaret.Gamalo@pfizer.com1∗ ShiHeliang1 ZhaoYuxi1 KudelaMaria1 Inflammation and Immunology Biometrics Strategy, Pfizer Research and Development, USA

Main article: https://doi.org/10.6339/24-JDS1161.

Corresponding author. Email: Margaret.Gamalo@pfizer.com. 20254220252313847 2025 The Author(s). Published by the School of Statistics and the Center for Applied Statistics, Renmin University of China.2025 Open access article under the CC BY license. References Ibrahim JG, Chen M-H (2000). Power prior distributions for regression models. Statistical Science, 15(1): 46–60. https://doi.org/10.1214/ss/1009212673 Chen M-H, Guan Z, Lin M, Sun M (2025). Power priors for leveraging historical data: looking back and looking forward. Journal of Data Science, 23(1): 1–30. https://doi.org/10.6339/24-JDS1161 Duan Y, Ye K, Smith EP (2006). Evaluating water quality using power priors to incorporate historical information. Environmetrics: The Official Journal of the International Environmetrics Society, 17(1): 95–106. https://doi.org/10.1002/env.752 Bernardo JM (1996). The concept of exchangeability and its applications. Far East Journal of Mathematical Sciences, 4: 111–122. Pawel S, Aust L, Held L, Wagenmakers E-J (2023). Normalized power priors always discount historical data. Stat, 12(1): e591. https://doi.org/10.1002/sta4.591 Berger J, Berliner LM (1986). Robust bayes and empirical bayes analysis with ε-contaminated priors. The Annals of Statistics, 14(2): 461–486. Schmidli H, Gsteiger S, Roychoudhury S, O’Hagan A, Spiegelhalter D, Neuenschwander B (2014). Robust meta-analytic-predictive priors in clinical trials with historical control information. Biometrics, 70(4): 1023–1032. https://doi.org/10.1111/biom.12242 Izem R, Buenconsejo J, Davi R, Luan JJ, Tracy L, Gamalo M (2022). Real-world data as external controls: practical experience from notable marketing applications of new therapies. Therapeutic Innovation & Regulatory Science, 56(5): 704–716. https://doi.org/10.1007/s43441-022-00413-0 Lin J, Gamalo-Siebers M, Tiwari R (2022). Ensuring exchangeability in data-based priors for a bayesian analysis of clinical trials. Pharmaceutical Statistics, 21(2): 327–344. https://doi.org/10.1002/pst.2172 Job KM, Gamalo M, Ward RM (2019). Pediatric age groups and approach to studies. Therapeutic Innovation & Regulatory Science, 53(5): 584–589. https://doi.org/10.1177/2168479019856572 Gamalo M, Bucci-Rechtweg C, Nelson RM, Vanh L, Porcalla A, Thackray H, et al. (2022). Extrapolation as a default strategy in pediatric drug development. Therapeutic Innovation & Regulatory Science, 56(6): 883–894. https://doi.org/10.1007/s43441-021-00367-9 Gamalo MA, Tiwari RC, LaVange LM (2014). Bayesian approach to the design and analysis of non-inferiority trials for anti-infective products. Pharmaceutical Statistics, 13(1): 25–40. https://doi.org/10.1002/pst.1588